Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics. CA Cancer J Clin. 2008, 58 (2): 71-96. 10.3322/CA.2007.0010
Article
PubMed
Google Scholar
Hadaschik BA, Gleave ME: Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol. 2007, 25: 413-9.
Article
CAS
PubMed
Google Scholar
Lucas A, Petrylak DP: The case for early chemotherapy for the treatment of metastatic disease. J Urol. 2006, 176 (6): S72-5. 10.1016/j.juro.2006.06.077
Article
CAS
PubMed
Google Scholar
Haqqani AS, Sandhu JK, Birnboim HC: Expression of Interleukin-8 promotes neutrophil infiltration and genetic instability in mutant tumors. Neoplasia. 2000, 2 (6): 561-68. 10.1038/sj.neo.7900110
Article
PubMed Central
CAS
PubMed
Google Scholar
Bischoff DS, Zhu JH, Makhijani NS, Kumar A, Yamaguchi DT: Angiogenic CXC chemokine expression during differentiation of human mesenchymal stem cells towards the osteoblastic lineage. J Cell Biochem. 2008, 103: 812-24. 10.1002/jcb.21450
Article
CAS
PubMed
Google Scholar
Xie K: Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001, 12: 375-91. 10.1016/S1359-6101(01)00016-8
Article
CAS
PubMed
Google Scholar
Kunsch C, Lang RK, Rosen CA, Shannon FM: Synergistic transcriptional activation of the IL-8 gene by NF-KB p65 (RelA) and NF-11-6. J Immunol. 1994, 153: 1153-64.
Google Scholar
Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J, Stratford IJ, Williams KJ, Johnston PG, Waugh DJ: HIF-1 and NF-k B-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene. 2007, 26: 7333-7345. 10.1038/sj.onc.1210536
Article
CAS
PubMed
Google Scholar
Chavey C, Mühlbauer M, Bossard C, Freund A, Durand S, Jorgensen C, Jobin C, Lazennec G: Interleukin-8 expression is regulated by histone deacetylases through the NF-{kappa}B pathway in breast cancer. Mol Pharmacol. 2008, 74: 1359-66. 10.1124/mol.108.047332
Article
CAS
PubMed
Google Scholar
Kumar P, Ning Y, Polverini PJ: Endothelial cells expressing Bcl-2 promote tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion. Lab Invest. 2008, 88: 740-49. 10.1038/labinvest.2008.46
Article
CAS
PubMed
Google Scholar
Singh S, Sadanandam A, Singh RK: Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev. 2007, 26: 453-67. 10.1007/s10555-007-9068-9
Article
PubMed Central
CAS
PubMed
Google Scholar
Kamohara H, Takahashi M, Ishiko T, Ogawa M, Baba H: Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells: Impact of CXCL-8 as an autocrine growth factor. Int J Oncol. 2007, 31: 627-32.
CAS
PubMed
Google Scholar
Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI: Structure and functional expression of a human interleukin-8 receptor. Science. 1991, 253: 1278-80. 10.1126/science.1840701
Article
CAS
PubMed
Google Scholar
Feniger-Barish R, Belkin D, Zaslaver A, Gal S, Dori M, Ran M, Ben-Baruch A: GCP-2-induced internalization of IL-8 receptors: hierarchical relationships between GCP-2 and other ELR1-CXC chemokines and mechanisms regulating CXCR2 internalization and recycling. Blood. 2000, 95: 1551-59.
CAS
PubMed
Google Scholar
Allen SJ, Crown SE, Handel TM: Chemokine: Receptor structure, interactions, and antagonism. Annu Rev Immunol. 2007, 25: 787-820. 10.1146/annurev.immunol.24.021605.090529
Article
CAS
PubMed
Google Scholar
Tanaka T, Bai Z, Srinoulprasert Y, Yang B, Hayasaka H, Miyasaka M: Chemokines in tumor progression and metastasis. Cancer Sci. 2005, 96: 317-22. 10.1111/j.1349-7006.2005.00059.x
Article
CAS
PubMed
Google Scholar
Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, Morris SB, Glass M, Wilke C, Xue YY, Sitterding S, Kunkel SL, Burdick MD, Strieter RM: Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol. 1999, 154: 1503-12.
Article
PubMed Central
CAS
PubMed
Google Scholar
Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston PG, Montironi R, Waugh DJ: Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res. 2005, 11: 4117-27. 10.1158/1078-0432.CCR-04-1518
Article
CAS
PubMed
Google Scholar
Patel BJ, Pantuck AJ, Zisman A, Tsui KH, Paik SH, Caliliw R, Sheriff S, Wu L, deKernion JB, Tso CL, Belldegrun AS: CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. J Urol. 2000, 164 (4): 1420-5. 10.1016/S0022-5347(05)67210-2
Article
CAS
PubMed
Google Scholar
Tso CL, McBride WH, Sun J, Patel B, Tsui KH, Paik SH, Gitlitz B, Caliliw R, van Ophoven A, Wu L, deKernion J, Belldegrun A: Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J. 2000, 6 (4): 220-33.
CAS
PubMed
Google Scholar
Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB, Lokeshwar BL: Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 2007, 67: 6854-62. 10.1158/0008-5472.CAN-07-1162
Article
CAS
PubMed
Google Scholar
Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP: Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2000, 6: 2104-19.
CAS
PubMed
Google Scholar
Kim SJ, Uehara H, Karashima T, Mccarty M, Shih N, Fidler IJ: Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia. 2001, 3: 33-42. 10.1038/sj.neo.7900124
Article
CAS
PubMed
Google Scholar
MacManus CF, Pettigrew J, Seaton A, Wilson C, Maxwell PJ, Berlingeri S, Purcell C, McGurk M, Johnston PG, Waugh DJ: Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol Cancer Res. 2007, 5: 737-48. 10.1158/1541-7786.MCR-07-0032
Article
CAS
PubMed
Google Scholar
Grant S: Cotargetting survival signaling pathways in cancer. J Clin Invest. 2008, 118: 3003-06. 10.1172/JCI36898E1
Article
PubMed Central
CAS
PubMed
Google Scholar
Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 2006, 441: 431-6. 10.1038/nature04870
Article
CAS
PubMed
Google Scholar
Poirier GG: Poly (ADP-ribosylation) and apoptosis. Mol Cell Biochem. 1999, 199 (1–2): 125-37.
PubMed
Google Scholar
Duriez PJ, Shah GM: Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol. 1997, 75 (4): 337-49. 10.1139/bcb-75-4-337
Article
CAS
PubMed
Google Scholar
Cohen GM: Caspases: the executioners of apoptosis. Biochem J. 1997, 326 (Pt 1): 1-16.
Article
PubMed Central
CAS
PubMed
Google Scholar
Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U, Gleave ME: A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther. 2005, 4: 1689-98. 10.1158/1535-7163.MCT-05-0064
Article
CAS
PubMed
Google Scholar
Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN: Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol. 1993, 4 (6): 327-32.
CAS
PubMed
Google Scholar
Chipuk JE, Green DR: How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?. Trends Cell Biol. 2008, 18 (4): 157-64. 10.1016/j.tcb.2008.01.007
Article
PubMed Central
CAS
PubMed
Google Scholar
Adams JM, Cory S: Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol. 2007, 19 (5): 488-96. 10.1016/j.coi.2007.05.004
Article
PubMed Central
CAS
PubMed
Google Scholar
Galletti E, Magnani M, Renzulli ML, Botta M: Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. Chem Med Chem. 2007, 2 (7): 920-42.
Article
CAS
PubMed
Google Scholar
Beyaert R, Vanhaesebroeck B, Heyninck K, Boone E, De Valck D, Schulze-Osthoff K, Haegeman G, Van Roy F, Fiers W: Sensitization of tumor cells to tumor necrosis factor action by the protein kinase inhibitor staurosporine. Cancer Res. 1993, 53 (11): 2623-30.
CAS
PubMed
Google Scholar
Easton JB, Houghton PJ: mTOR and cancer therapy. Oncogene. 2006, 25 (48): 6436-46. 10.1038/sj.onc.1209886
Article
CAS
PubMed
Google Scholar
Fan X, Patera AC, Pong-Kennedy A, Deno G, Gonsiorek W, Manfra DJ, Vassileva G, Zeng M, Jackson C, Sullivan L, Sharif-Rodriguez W, Opdenakker G, Van Damme J, Hedrick JA, Lundell D, Lira SA, Hipkin RW: Murine CXCR1 is a functional receptor for GCP-2/CXCL6 and IL-8/CXCL8. J Biol Chem. 2007, 282: 11658-66. 10.1074/jbc.M607705200
Article
CAS
PubMed
Google Scholar
Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS: Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer. 2007, 56: 25-33. 10.1016/j.lungcan.2006.11.014
Article
CAS
PubMed
Google Scholar
Takeyama K, Mitsuzawa H, Shimizu T, Konishi M, Nishitani C, Sano H, Kunishima Y, Matsukawa M, Takahashi S, Shibata K, Tsukamoto T, Kuroki Y: Prostate cell lines secrete IL-8 in response to Mycoplasma hominis through Toll-like receptor 2-mediated mechanism. Prostate. 2006, 66: 386-91. 10.1002/pros.20358
Article
CAS
PubMed
Google Scholar
Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D, Corey E: Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 2003, 97 (5): 1211-6. 10.1002/cncr.11178
Article
CAS
PubMed
Google Scholar
Caruso DJ, Carmack AJ, Lokeshwar VB, Duncan RC, Soloway MS, Lokeshwar BL: Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res. 2008, 14: 4111-8. 10.1158/1078-0432.CCR-08-0738
Article
PubMed Central
CAS
PubMed
Google Scholar
Lindholm PF, Bub J, Kaul S, Shidham VB, Kajdacsy-Balla A: The role of constitutive NF-kB activity in PC-3 human prostate cancer cell invasive behavior. Clin Exp Metastasis. 2001, 18: 471-9. 10.1023/A:1011845725394.
Article
Google Scholar
Wilson C, Purcell C, Seaton A, Oladipo O, Maxwell PJ, O'Sullivan JM, Wilson RH, Johnston PG, Waugh DJ: Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther. 2008, 327: 746-59. 10.1124/jpet.108.143826
Article
CAS
PubMed
Google Scholar
Martin D, Galisteo R, Gutkind JS: CXCL8/IL8 Stimulates Vascular Endothelial Growth Factor (VEGF) Expression and the Autocrine Activation of VEGFR2 in Endothelial Cells by Activating NF{kappa}B through the CBM (Carma3/Bcl10/Malt1) Complex. J Biol Chem. 2009, 284: 6038-42. 10.1074/jbc.C800207200
Article
PubMed Central
CAS
PubMed
Google Scholar
Inou K, Wood CG, Slaton JW, Karashima T, Sweeney P, Dinney CP: Adenoviral-Mediated gene therapy of human bladder cancer with antisense interleukine-8. Oncol Rep. 2001, 8: 955-64.
Google Scholar
Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS: NF-kB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998, 281: 1680-3. 10.1126/science.281.5383.1680
Article
CAS
PubMed
Google Scholar
Wang CY, Guttridge DC, Mayo MW, Baldwin AS: NF-kB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol. 1999, 19: 5923-9.
PubMed Central
CAS
PubMed
Google Scholar
Cusack JC, Liu R, Baldwin AS: NF-kB and chemoresistance: potentiation of cancer drugs via inhibition of NF-kB. Drug Resist Updat. 1999, 2: 271-3. 10.1054/drup.1999.0094
Article
CAS
PubMed
Google Scholar
McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992, 52: 6940-4.
CAS
PubMed
Google Scholar
Apakama I, Robinson MC, Walter NM, Charlton RG, Royds JA, Fuller CE, Neal DE, Hamdy FC: bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer. 1996, 74: 1258-62.
Article
PubMed Central
CAS
PubMed
Google Scholar
Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol. 1993, 143: 390-400.
PubMed Central
CAS
PubMed
Google Scholar
Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ: Interleukin-8 signaling promotes androgen-indpendent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis. 2008, 29: 1148-1156. 10.1093/carcin/bgn109
Article
CAS
PubMed
Google Scholar
Karl E, Warner K, Zeitlin B, Kaneko T, Wurtzel L, Jin T, Chang J, Wang S, Wang CY, Strieter RM, Nunez G, Polverini PJ, Nör JE: Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kB and CXC chemokines. Cancer Res. 2005, 65: 5063-5069. 10.1158/0008-5472.CAN-05-0140
Article
CAS
PubMed
Google Scholar
Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke U, Gleave ME: Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes. BJU Int. 2006, 97: 1300-08. 10.1111/j.1464-410X.2006.06147.x
Article
CAS
PubMed
Google Scholar
Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright GL, Vessella RL, Ralph D: Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology. 1999, 53: 139-47. 10.1016/S0090-4295(98)00455-5
Article
CAS
PubMed
Google Scholar
Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM: Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer. 2002, 98: 297-09. 10.1002/ijc.10168
Article
CAS
PubMed
Google Scholar
Dandekar DS, Lokeshwar BL: Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin Cancer Res. 2004, 10: 8037-47. 10.1158/1078-0432.CCR-04-1208
Article
CAS
PubMed
Google Scholar